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GINA classificationAbstract Objective: To determine the prevalence of vitamin D deficiency in patients with COPD
and bronchial asthma, and the relation of vitamin D serum levels to pulmonary spirometric mea-
sures as well as other important clinical parameters that could affect quality of life in these patients.
Subjects and methods: The study included 80 subjects: 30 patients with COPD and 30 patients
with bronchial asthma and 20 healthy volunteers. Patients and control groups were subjected to
vitamin D assay by ELISA as well as spirometric assessment. Assessment of patients with COPD
was done according to GOLD guidelines 2013: using (mMRCs), CAT score, spirometric assessment
of FEV1, and exacerbation assessment. They were also subjected to Combined COPD assessment
and BODE index calculation. For all patients with bronchial asthma, GINA classification 2014
of bronchial asthma severity and asthma control assessment were done.
Results: Statistically significant lower values of vitamin D were found in patients with COPD
(11.94 ± 7.66 ng/ml) compared to patients with bronchial asthma (22.03 ± 8.19 ng/ml) with
p< 0.001, while mean ± SD values of 25-hydroxy vitamin D of both groups of patients (COPD
and bronchial asthma) were statistically significant lower than control group (35.21 ± 6.04 ng/
ml) with (p2, p3 < 0.001) respectively. Seventeen patients that is to say (56.7%) of patients with
COPD and 11 patients that is to say (36.7%) patients with bronchial asthma demonstrated a mild
to moderate degree of vitamin D deficiency, whereas 13 that is to say (43.3%) patients of COPD
and 4 that is to say (13.3%) patients with bronchial asthma showed severe deficiency and all control
subjects (n= 20) had a normal concentration of 25-hydroxy vitamin D. Statistically significant pos-
itive correlation was found between serum level of 25-hydroxy vitamin D and FEV1% of predicted
in patients with COPD with (p= 0.002), whereas no statistically significant correlation was found
between serum level of 25-hydroxy vitamin D and FEV1% of predicted in patients with bronchial
asthma with (p= 0.120). Statistically significant negative correlations existed between serum level
of 25-hydroxy vitamin D and exacerbation risk of patients with COPD and bronchial asthma with
390 E. Gouda et al.(rs = 0.481 and p= 0.007), and (rs = 0.496 and p= 0.005), respectively. Statistically significant
negative correlations were found between serum level of 25-hydroxy vitamin D and exacerbation risk
of patients with COPD and bronchial asthma with (rs = 0.481 and p= 0.007), and (rs = 0.496
and p= 0.005), respectively. Regarding relation between vitamin D level and grading severity of
COPD, we found a significant correlation between serum 25-hydroxy vitamin D level and severity
of COPD as assessed by GOLD spirometric classification, with decreased serum level of vitamin
D as gold severity increased (19.12 ± 4.37, 9.97 ± 7.64, 8.21 ± 5.72 ng/ml) in gold I, II, III respec-
tively with p= 0.012. Also it was found that CAT score increased and got worse as serum level of
vitamin D decreased (16.65 ± 6.98, 8.68 ± 2.27, 9.01 ± 5.67 ng/ml) in categories II, III, IV respec-
tively with rs = 0.468 and p= 0.034, and according to Combined COPD assessment, vitamin D
levels were (19.78 ± 4.66, 17.38 ± 4.59, 6.75 ± 4.77, 7.56 ± 5.83 ng/ml) in groups A, B, C and D
respectively with rs = 0.448 and p= 0.001. A statistically significant negative correlation was
found between serum 25-hydroxy vitamin D level and BODE index score of COPD assessment with
rs = 0.421, p= 0.020. According to the correlation of bronchial asthma severity and control to
serum level of 25-hydroxy vitamin D, we found a statistically significant negative correlation between
mean ± SD of serum level of 25-hydroxy vitamin D and different levels of asthma control with
(rs = 0.636, p< 0.001) as well as a statistically significant negative correlation between quantifica-
tion of 25-hydroxy vitamin D and levels of asthma severity with (rs = 0.875, p< 0.001).
Conclusion: Vitamin D deficiency was highly prevalent in COPD and bronchial asthma (100%
and 50%) respectively. Low levels of vitamin D were associated with low FEV1%, frequent exacer-
bations in patients with COPD and bronchial asthma, and increased COPD severity as assessed by
GOLD guidelines. Important statistically significant negative associations between vitamin D level
and both asthma control and asthma severity according to GINA classification were also found.
Thus it is advised to include vitamin D levels in the routine assessment of patients with bronchial
asthma and COPD, as well as studying the importance and clinical impact of oral supplementation
of vitamin D in patients with COPD and bronchial asthma should be an important goal of future
research.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Vitamin D (D represents D2, D3, or both) is a secosterol pro-
duced endogenously in the skin from sun exposure or obtained
from foods that naturally contain vitamin D, including cod
liver oil and fatty fish (e.g.: salmon, mackerel, and tuna);
UV-irradiated mushrooms; foods fortified with vitamin D;
and supplements [1]. The plasma 25(OH)D concentration is
a useful vitamin D biomarker because it has a long half-life
in the circulation; its concentration is not under tight homeo-
static regulation. This biomarker therefore reflects vitamin D
supply and usage over a period of time [2]. Many effects of
vitamin D have been found to occur outside the feedback-
controlled osseous endocrine loop and to be independent from
serum calcium, phosphorus, or PTH levels [3]. There have been
numerous studies looking at vitamin D status in association
with various lung diseases focusing on asthma, chronic
obstructive pulmonary disease (COPD), and respiratory infec-
tions, these studies have demonstrated a high prevalence of
vitamin D deficiency in their participants [4]. In this study,
we used ELISA as the most popular method for the measure-
ment of plasma 25(OH)D concentration, we evaluated pul-
monary function tests (FEV1% of predicted) using the
spirometry, exacerbation risks, and GOLD guidelines 2013
that suggested the assessment of the severity of COPD not only
by FEV1% but also by symptom scoring (e.g., mMRC dysp-
nea scale or CAT score), and the frequency of acute exacerba-
tions of COPD [5], B. asthma assessment by GINA guidelines
2014.Aim of the Work
Studying the pattern of vitamin D in patients with COPD and
bronchial asthma by finding the relation of mean level of vita-
min D to different parameters in those patients, such as demo-
graphic data, pulmonary function tests, exacerbation
frequency, COPD severity, asthma control and severity.
Methods
The study was conducted on 30 patients with COPD, 30
patients with B. asthma and 20 healthy volunteers, they were
recruited from El-Maamora Chest Hospital in the period from
September 2014 to May 2015, all individuals were subjected to:
 Detailed medical history.
 Clinical examination.
 Demographic data, BMI assessment.
 Laboratory investigations: complete blood picture (white
blood cell, red blood cell count and hemoglobin level), fast-
ing and random blood sugar, blood urea, creatinine, SGOT
and SGPT.
 Arterial blood gases and acid–base balance: oxygen satura-
tion (SaO2), PH, PaO2, PaCO2, HCO3
 meq/L.
 C-reactive protein: normal level between (1.0 and 3.0 mg/L).
 Detailed computerized pulmonary function tests: using
(CHESTGRAPH HI-701) high grade spirometer [6]. Pul-
monary function tests include (FVC)% of predicted,
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FEV1/FVC %, post-bronchodilator FVC (L), we per-
formed bronchodilator reversibility testing using 2, 4, 6
and maximum of 8 puffs till obtaining positive bronchodila-
tor reversibility.
 Vitamin D assessment: (25-hydroxy vitamin D) was deter-
mined in the serum of all subjects in our study by ELISA
which is the most popular method for the measurement of
plasma 25(OH)D concentration [7].
 Assessment of C.O.P.D according to GOLD guidelines
2013: using (mMRCs), CAT score, spirometric assessment
of FEV1, and exacerbation assessment.
 Combined COPD assessment: by combining spirometric
assessment and exacerbation risk, patients were divided to
four groups (Fig. 1) [8].
– Group A: low risk, low symptoms.
– Group B: low risk, high symptoms.
– Group C: high risk, low symptoms.
– Group D: high risk, high symptoms.
 Assessment quality of life in patients with COPD: by mea-
suring BODE index through four factors (post-
bronchodilator FEV1%, dyspnea, BMI and 6-min walk
test).
 GINA classification 2014 of asthma severity and asthma
control.
Results
Subjects were divided into:
Group I: 30 patients with COPD,Figure 1 Chart of CombiGroup II: 30 patients with bronchial asthma and
Group III: 20 healthy volunteers,
The three groups were subjected to vitamin D assessment
and the relation of vitamin D level to different parameters
was studied, comparison of laboratory reference and quantifi-
cation of vitamin D in the three studied groups is shown in
(Table 1).
– Demographic data (age and gender) in relation to vitamin
D level in the studied groups are shown in (Tables 2 and 3)
The study showed that mean ± SD of 25-hydroxy vitamin
D of COPD group was 11.94 ± 7.66 ng/ml, with statistically
significant lower value than bronchial asthma p1 < 0.001 as
mean ± SD of 25-hydroxy vitamin D of bronchial asthma
was 22.03 ± 8.19 ng/ml, while mean ± SD of 25-hydroxy
vitamin D of both COPD group and bronchial asthma group
had a statistically significant lower value than control group
(p2, p3 < 0.001) respectively, and mean ± SD of 25-hydroxy
vitamin D of control group was 35.21 ± 6.04 ng/ml (see
Tables 4–7).
Also a statistically significant correlation existed between
Laboratory references of 25-hydroxy vitamin D level (optimal,
mild to moderate and severe) and each of the studied group
(COPD, bronchial asthma and control) with p< 0.001. As
regarding demographic data, we found no statistically signifi-
cant correlation between serum level of 25-hydroxy vitamin
D and age of patients with COPD and patients with B. asthma
and control group with (rs= 0.249, p= 0.185), (rs= 0.253
and p= 0.178) and (rs = 0.012 and p= 0.960) respectively.
As regarding correlation of vitamin D level to gender in eachned COPD assessment.
Table 1 Comparison between the studied groups according to Quantification and Laboratory reference of 25-hydroxy vitamin D.
COPD (n= 30) Bronchial asthma (n= 30) Control (n= 20) Test of sig. p
No. % No. % No. %
Quantification of 25-hydroxy vitamin D
Min.–Max. 0.95–23.80 0.93–31.61 25.49–45.88 KWv2 = 50.771* <0.001*
Mean ± SD. 11.94 ± 7.66 22.03 ± 8.19 35.21 ± 6.04
Median 11.63 24.06 36.16
Sig.bet.Grps p1 < 0.001
*, p2 < 0.001
*, p3 < 0.001
*
Laboratory reference of 25-hydroxy vitamin D
Optimal 0 0.0 15 50.0 20 100.0 v2 = 50.924* <0.001*
Mild to moderate deficiency 17 56.7 11 36.7 0 0.0
Severe deficiency 13 43.3 4 13.3 0 0.0
Sig.bet.Grps p1 < 0.001
*, p2 < 0.001
*, p3 < 0.001
*
Demographic data (age and gender) in relation to vitamin D level in the studied groups are shown in Tables 2 and 3.
Table 2 Correlation between quantification of 25-hydroxy
vitamin D with age (years) in each group.
Quantification of 25-hydroxy vitamin D
COPD Bronchial asthma Control
rs p rs p rs p
Age (years) 0.249 0.185 0.253 0.178 0.012 0.960
Table 3 Correlation between quantification of 25-hydroxy
vitamin D and gender in each group.
Vitamin D Gender Z p
Male Female
COPD N= 30 N= 0
Min.–Max. 0.95–23.80 – – –
Mean ± SD 11.94 ± 7.66 –
Median 11.63 –
Bronchial Asthma N= 4 N= 26
Min.–Max. 3.49–27.87 0.93–31.61 1.159 0.246
Mean ± SD 15.73 ± 11.44 23.0 ± 7.40
Median 15.78 24.64
Control N= 12 N= 8
Min.–Max. 25.49–45.88 26.14–42.30 1.389 0.165
Mean ± SD 33.79 ± 6.14 37.35 ± 5.57
Median 33.62 39.31
Table 4 Correlation between quantification of 25-hydroxy
vitamin D and different parameters in both COPD and
bronchial asthma group.
Quantification of 25-hydroxy vitamin D
COPD Bronchial asthma
rs p rs p
Exacerbation risk
(per year)
0.481* 0.007* 0.496* 0.005*
FEV1 (predicted)% 0.548
* 0.002* 0.290 0.120
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serum level of 25-hydroxy vitamin D and the gender of
patients in COPD group and the gender in control group with
(p= 0.246, p= 0.165) respectively. Mean ± SD of risk exac-
erbation in patients with COPD was 2.73 ± 1.78 per year,
while mean ± SD of exacerbations (per year) of bronchial
asthma group was 0.70 ± 0.99, also we found a statistically
significant negative correlation between serum level of 25-
hydroxy vitamin D and exacerbation risk of patients with
COPD (rs= 0.481 and p= 0.007) and statistically signifi-
cant negative correlation between serum level of 25-hydroxyvitamin D and exacerbation risk of patients with bronchial
asthma (rs = 0.496 and p= 0.005). By comparing FEV1%
(predicted) in the three groups of the study, we found mean
± SD of FEV1% (predicted) in COPD group was 64.07
± 19.23%, while mean ± SD of FEV1% (predicted) in B.
asthma was 73.75 ± 13.10% with a statistically significant
lower value in COPD than B. asthma (p1 = 0.013), while
mean ± SD of FEV1% (predicted) in the control group was
91.20 ± 7.17% with a statistically significant higher value than
COPD group and B. asthma group (p2, p3 < 0.001) and by the
correlation of FEV1% with vitamin D level, we found a statis-
tically significant positive correlation between serum level of
25-hydroxy vitamin D and FEV1% of predicted in COPD
group (rs= 0.548 and p= 0.002), while no statistically signif-
icant correlation between serum level of 25-hydroxy vitamin D
and FEV1% of predicted in B. asthma group (rs = 0.290 and
p= 0.120). According to the distribution of the studied COPD
cases according to gold spirometric classification (FEV1% of
predicted), we found 8 (26.7%) of patients with COPD had
FEV1% of predicted P80, 14 (46.7%) of the studied COPD
group had FEV1% of predicted from 50% to 80%, and 8
(26.7%) of COPD patients of the studied COPD group had
FEV1% of predicted from 30% to 50%. No patient of the
studied COPD group had FEV1% of predicted less than 30%.
Regarding relation between vitamin D level and grading
severity of COPD, we found a significant correlation between
serum 25-hydroxy vitamin D level and severity of COPD as
assessed by GOLD spirometric classification, with decreased
serum level of vitamin D as gold severity increased (19.12 ±
Table 5 Relation between quantification of 25-hydroxy vitamin D and grading of severity of COPD group.
Vitamin D N COPD
Min.–Max. Mean ± SD Median
Gold spirometric classification
Gold 1 8 11.02–23.41 19.12 ± 4.37 20.55
Gold 2 14 0.95–23.80 9.97 ± 7.64 9.07
Gold 3 8 2.60–19.13 8.21 ± 5.72 6.22
Gold 4 0 – – –
KWv2(p) 8.895*(0.012*)
CAT score
Category 1(0–9 The best) 0 – – –
Category 2(10–19) 12 3.87–23.41 16.65 ± 6.98 19.11
Category 3(20–29) 11 0.95–23.80 8.68 ± 2.27 8.68
Category 4(30–40 The worst) 7 2.64–19.13 9.01 ± 5.67 6.37
KWv2(p) 6.751*(0.034*)
Combined COPD assessment
Low risk , less symptoms (Group A) 8 11.02–23.80 19.78 ± 4.66 21.70
Low risk , more symptoms (Group B) 4 11.49–22.59 17.38 ± 4.59 17.72
High risk , less symptoms (Group C) 7 0.95–13.02 6.75 ± 4.77 4.75
High risk , more symptoms (Group D) 11 1.12–19.13 7.56 ± 5.83 6.07
KWv2(p) 16.197*(0.001*)
Table 6 Relation between quantification of 25-hydroxy vitamin D and level of control in Bronchial asthma group.
Vitamin D N Bronchial Asthma
Min.–Max. Mean ± SD Median
Level of asthma control
Well controlled Bronchial asthma 21 19.44–3161 25.78 ± 3.50 26.18
Partly controlled B. asthma 6 0.93–25.41 14.76 ± 8.87 16.44
Uncontrolled B. asthma 3 3.42–23.98 10.30 ± 11.85 3.49
KWv2(p) 11.993*(0.002*)
rs (p) 0.636*(<0.001*)
Table 7 Relation between quantification of 25 hydroxyl vitamin Dwith level of asthma severity.
Vitamin D N Bronchial Asthma
Min.–Max. Mean ± SD Median
Asthma severity
Intermittent B. asthma 14 24.13–31.61 27.57 ± 2.23 27.33
Mild persistent B. asthma 9 19.19–28.54 22.88 ± 2.52 22.69
Moderate persistent B. asthma 6 0.93–19.44 10.03 ± 8.43 8.60
Severe persistent B. asthma 1 8.87
KWv2(p) 22.449*(<0.001*)
rs (p) 0.875*(<0.001*)
Patterns of vitamin D 3934.37, 9.97 ± 7.64, 8.21 ± 5.72 ng/ml) in gold I, II, III respec-
tively with p= 0.012. CAT score increased and got worse as
serum level of vitamin D decreased (16.65 ± 6.98, 8.68
± 2.27, 9.01 ± 5.67 ng/ml) in categories II, III, IV respectively
with rs = 0.468, p= 0.034, and according to Combined
COPD assessment, vitamin D levels were (19.78 ± 4.66,
17.38 ± 4.59, 6.75 ± 4.77, 7.56 ± 5.83 ng/ml) respectively
in groups A, B, C and D with rs = 0.448 and p= 0.001. A
statistically significant negative correlation was found between
serum 25-hydroxy vitamin D level and BODE index score of
COPD assessment with rs= 0.421, p= 0.020.Assessment of bronchial asthma control was done accord-
ing to the following items (limitation of activities, nocturnal
symptoms, daytime symptoms (per week), need for reliever
(per week), exacerbations (per year)), in addition to FEV1%
of predicted, and by those items patients with bronchial
asthma were classified; 21 patients of B. asthma (70%) were
classified as well controlled bronchial asthma, and 6 patients
of bronchial asthma (20%) were classified as partly controlled
B. asthma, while 3 patients of B. asthma (10%) were classified
as uncontrolled B. asthma by assessment of asthma severity
according to: (symptoms, nighttime awakenings, short-acting
394 E. Gouda et al.Beta 2 agonist, interference with normal activity, exacerbation
risk), we found 14 patients of bronchial asthma 46.7% were
classified as intermittent B. asthma, 9 patients of bronchial
asthma 30% were classified as mild persistent B. asthma, 6
patients of bronchial asthma 20% were classified as moderate
persistent bronchial asthma, and 1 patient of bronchial asthma
3.3% was classified as severe persistent bronchial asthma.
According to the correlation of bronchial asthma severity
and control to serum level of 25-hydroxy vitamin D we
found a statistically significant negative correlation between
mean ± SD of serum level of 25-hydroxy vitamin D and dif-
ferent levels of asthma control with (rs = 0.636, p< 0.001)
and a statistically significant negative correlation between
quantification of 25-hydroxy vitamin D and levels of asthma
severity with (rs = 0.875, p< 0.001).Discussion
Worldwide, COPD is in the spotlight, because its high preva-
lence, morbidity, and mortality create formidable challenges
for healthcare systems [9]. Recent studies showed that a sub-
stantial proportion of patients with chronic obstructive pul-
monary disease have deficient vitamin D levels [10–12]. On
the other hand, several epidemiological studies have suggested
that vitamin D deficiency is associated with an increased inci-
dence of bronchial asthma and allergy symptoms, and a num-
ber of hypotheses have been advanced to explain the
pathogenetic link between bronchial asthma and vitamin D
deficiency [3].
Regarding spectrum of vitamin D deficiencies among our
studied populations, 17 (56.7%) of patients with COPD and
11 (36.7%) patients with bronchial asthma demonstrated a
mild to moderate degree of deficiency, whereas 13 (43.3%)
patients of COPD and 4 (13.3%) patients with bronchial
asthma showed a severe deficiency and all control subjects
(n= 20) had a normal concentration of 25-hydroxy vitamin
D with total (p< 0.001). Our findings are consistent with
those of Kunisaki et al. [13], Franco et al. [14], Holmgaard
et al. [15], Mahlin et al. [16], Puhan et al. [17] and, Romme
et al. [18]. They found that the prevalence of hypovitaminosis
D in COPD patients varies between 31% and 77% where the
majority of COPD patients had vitamin D deficiency and the
estimated risk for vitamin D deficiency was shown to be higher
in COPD patients compared to control subjects, while Mekov
et al. [19] found variability in the prevalence of hypovita-
minosis D as compared to previous studies, these results could
be explained with differences in lifestyle between the popula-
tions in different studies (outdoor activities, skin protection,
sunlight exposure. . . etc.), as well as according to prevalence
of exacerbation. Freishtat et al. in year 2010 [20] tried to assess
if low vitamin D levels have been implicated in the develop-
ment of and increased morbidity from asthma, they found that
the prevalence of vitamin D deficiency was significantly greater
among cases with B. asthma than controls 46/85 (54%) vs.
1/21 (5%).
In our study, no statistical correlation was observed
between serum level of 25-hydroxy vitamin D and age of
patients of B. asthma and COPD and subjects of the control
group, also no difference between females or males as regard-
ing vitamin D levels. In our study females were not included in
our patients with COPD (one of our study limitations), sodemographic data and anthropometric data were independent
predictors of vitamin D level.
Spirometry was done for all subjects in our study, Forced
expiratory volume in one second (FEV1), is the principal mea-
sure of lung function, its importance is an objective index of
airflow obstruction. Our finding was that FEV1% in patients
with COPD was correlated with vitamin D level while there
was no relation of FEV1% in patients with B. asthma with
vitamin D level.
Our findings are against the study of Korn et al. [21], Eman
Sheble et al. [22] and Chinese study of Li et al. [23], they found
that serum 25(OH)D levels were positively correlated with
FEV1% of predicted in patients with bronchial asthma but
coincided with studies of Janssen et al. [11] and Ferrari et al.
[24] in patients with COPD, where both studies observed a
positive correlation between 25(OH)D and FEV1% in patients
with chronic obstructive pulmonary disease (COPD) with
(r= 0.28, p< 0.0001) and (rs = 0.896 and p= 0.001)
respectively.
Lehouck et al. in 2012 [25] defined COPD exacerbations as
sustained worsening of respiratory symptoms during 48 h and
requiring oral corticosteroid, antibiotic, or combination treat-
ment that was initiated by a physician. Respiratory symptoms
included at least 1 of the Anthonisen criteria (increased dysp-
nea, sputum volume, or sputum purulence) with or without
minor symptoms, such as cough, fever, common cold, wheez-
ing, or sore throat [26]. According to our findings mean
± SD of risk exacerbation in patients with COPD was
2.73 ± 1.78 per year, while mean ± SD of exacerbations
(per year) of bronchial asthma group was 0.70 ± 0.99, and sig-
nificant correlation between serum level of 25-hydroxy vitamin
D and exacerbation risk of patients in COPD group and
patients with bronchial asthma, both Holmgaard et al. [15]
and Quint et al. [27] have findings that support the published
studies in which the investigators were unable to find a signif-
icant correlation between 25-(OH)D levels and exacerbation
frequency in patients with COPD, while Malinovschi et al. in
2014 [28] analyzed vitamin D levels and showed that the higher
the number of AECOPD the lower the vitamin D level
(p< 0.001). The relation between severe vitamin D deficiency
and frequent exacerbations was consistent after further adjust-
ing for all the comorbidities (p= 0.03). However, the role of
vitamin D deficiency in AECOPD is still debated. In agree-
ment with our study, Brehm and colleagues in 2012 [29] con-
ducted a longitudinal study of serum vitamin D and severe
asthma exacerbations. In that study, vitamin D deficiency
(25[OH]D level <30 ng/ml) at baseline was associated with
an increased risk of severe asthma exacerbations.
In linking low 25-hydroxy vitamin D levels with disease
severity, statistical significant correlation was found between
quantification of 25-hydroxy vitamin D and levels of
asthma severity with decreased vitamin D (27.57 ± 2.23,
22.88 ± 2.52, 10.03 ± 8.43, 8.87 ng/ml) with increased sever-
ity of B. asthma . In agreement with our results, Mohamed
et al. [5] in 2015 suggested the potential role of serum vitamin
D levels in patients with B. asthma, affecting its degree of
severity, also Montero-Arias et al. in 2013 [30] assessed a sta-
tistically significant relationship between asthma severity and
vitamin D sufficiency status . We found a decreased level of
vitamin D with decreased control of B. asthma (25.78
± 3.50, 14.76 ± 8.87, 10.30 ± 11.85 ng/ml) respectively in
controlled, partly controlled and uncontrolled bronchial
Patterns of vitamin D 395asthma, our results were in line with the studies of Hamzaoui
et al. [31], Korn et al. [21] and Columbo et al. [32].
Korn et al. in 2013 [21], found that the frequency of vitamin
D insufficiency or deficiency was significantly higher in
patients with severe or uncontrolled asthma (24.2 ± 11.8 ng/
m), compared to partly controlled (25.9 ± 10.8 ng/ml) and
controlled bronchial asthma (29.5 ± 12.5 ng/ml) with
(p= 0.030). This study matching with our study results, as a
statistical significance correlation was found between the level
of asthma a control and serum concentration of 25-hydroxy
vitamin D with a lower concentration in uncontrolled asthma
than partly controlled and controlled asthma with (total
p= 0.002).
Based on GOLD guideline for grading severity of airway
obstruction, our studied COPD patients were stratified as 8
patients associated with mild obstruction and mean 25-
hydroxy vitamin D (19.12 ± 4.37 ng/ml) gold I, 14 patients
showed moderate obstruction (9.97 ± 7.64 ng/ml) gold II,
while 8 patients showed severe obstruction (8.21 ± 5.72 ng/
ml) gold III, and no patient showed very severe obstruction.
Our study demonstrated a negative significant correlation
between serum level of 25-hydroxy vitamin D and gold spiro-
metric classification in patients with COPD (rs = 0.496 and
p= 0.005).
By our study, Combined COPD assessment (CCQ) was
negatively correlated with the level of 25-hydroxy vitamin D
with (rs = 0.666 and p< 0.001). We assessed other parame-
ters in patients with COPD as BODE index and CAT score, we
found that 25-hydroxy vitamin D was negatively correlated
with BODE index (rs= 0.421, p= 0.020), and negatively
correlated with CAT score (rs = 0.468, p= 0.009), 25-
hydroxy vitamin D level decreased with an increase in CAT
score from CAT score II onward to IV score, however 25-
hydroxy vitamin D was positively correlated with 6-min walk
test (rs = 0.514 and p= 0.004). Said and Abd El-naeem in
2015 [33] detected a negative correlation between vitamin D
with CAT score among patients with COPD (rs = 0.24,
p= 0.04). On the other hand, there was no correlation
between vitamin D and 6-min walk test (6-MWT) in patients
with COPD (rs = 0.10, p= 0.4) and among the control group
(rs = 0.15, p= 0.5).
BODE provides an integrated evaluation of the respiratory
and non-respiratory expressions of the disease, that better
reflects disease severity [34]. The author Celli in 2008 presented
an approach to patients with COPD and showed that dyspnea
measured with simple tools such as the modified Medical
Research Council scale, the body mass index, and the timed
6-min walk distance are all better predictors of mortality than
FEV1, the incorporation of these variables into the multidi-
mensional BODE index (body mass index, airflow obstruction,
dyspnea, exercise capacity) predicts survival even better [35].
According to Menon et al. in 2014 [36], Vitamin D correlated
negatively with GOLD severity grade (0.406), BODE index
(0.408), CCQ (0.495), exacerbation rate (0.536) and
GOLD staging (0.369). These correlations were highly signif-
icant (p< 0.01). Vitamin D levels decreased with an increasing
severity of COPD disease. In a recent study on COPD patients
by Janssens et al. in 2010 [11], they found a strong relationship
between GOLD stage and vitamin D deficiency suggesting a
relationship with airway obstruction. Although the mean 25-
OHD levels in GOLD 1 (22.4 ng/ml) were not significantly dif-
ferent from those of the control population, average 25-OHDlevels further decreased with the increasing GOLD stage. Also
matching with our results, Persson et al. in 2012 [10] found that
a higher GOLD stage associated with significantly lower levels
of serum 25(OH)D levels in patients with COPD, with a value
of 22.7 ± 9.3 ng/ml and 21.6 ± 10.00 ng/ml in GOLD stage
III–IV, respectively, while in contrast, Holmgaard et al. in
2013 [15] demonstrated no significant difference between 25-
hydroxy vitamin D and severity of COPD p= 0.55.Conclusions
Vitamin D deficiency was highly prevalent in COPD and bron-
chial asthma (100% and 50%) respectively that was attributed
to several factors including seasonal variation and latitude,
and time spent indoors which reduces the ability of the skin
to produce vitamin D by as much as 95–99%.
The Complexity of COPD and its frequent comorbidities
requires assessment and staging of the disease beyond the
degree of airflow limitation. Therefore, new GOLD guidelines
(2013) suggest the assessment of the severity of COPD not only
by FEV1% but also by symptom scoring (e.g., mMRC dysp-
nea scale or CAT score), and the frequency of acute exacerba-
tions of COPD and these conceptual changes reinforce the
importance of a good questionnaire in assessing the severity
of COPD in clinical practice. Vitamin D deficiency causing
an excessive adaptive immune response with a higher synthesis
of cytokines and increased bronchial inflammation that may
explain the higher probability of having acute exacerbations
in patients with B. asthma and COPD. The link between vita-
min D deficiency and asthma severity was related mainly to
greater airway hyper-responsiveness with airway remodeling.
Vitamin D should be considered as a routine assessment of
patients with bronchial asthma and COPD, as well as ensuring
the importance of oral supplementation of vitamin D in
patients with COPD and bronchial asthma.Conflict of interest
No conflict of interest.References
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